Help! Please Register

  The Fungi

  Introduction
  Descriptions
  Synonyms
  Image Bank
  Lecture Bank
  Video Bank


  Mycoses

  Introduction
  Human
  Veterinary
  Environmental
   Industrial
  Agricultural
  MSG


  Drugs

  Introduction
  Medical
  Veterinary
  Environmental
   Industrial
  Agricultural


  Laboratory

  Introduction
  Susceptibility
  MIC Database
  Procedures
  Histopathology


  Education &
  Tools

  Introduction
  Abbreviations
  Links
  CME
  Conference
   Highlights
  Bibliography
  Glossary
  Good Books
  Events Calendar


  About Us

  Introduction
  Our Mission
  Editorial Board
  Editorial Staff
  Supporters
  Contributors
  Legal Stuff
  Privacy Policy
  Kudos


  The Fungi

  Introduction
  Descriptions
  Synonyms
  Image Bank
  Lecture Bank
  Video Bank



This page updated:
1/27/2007 9:23:00 AM


DoctorFungus - All Rights Reserved © 2007 Copyright
& Privacy Policy


Site built and designed for doctorfungus by Webillustrated



You are here: The Fungi > Descriptions >


Histoplasma sp.
Darling, 1906

Say Me

Taxonomic classification

Kingdom: Fungi
Phylum: Ascomycota
Subphylum: Ascomycotina
Class: Ascomycetes
Order: Onygenales
Family: Onygenaceae
Genus: Ajellomyces (Histoplasma)

Description and Natural Habitats

Histoplasma is a thermally dimorphic fungus found in nature. Soil contaminated with bird droppings or excrements of bats is the common natural habitat for Histoplasma. Although it is claimed to exist worldwide, tropical areas are where this fungus is more frequently encountered. It is endemic in the Tennessee-Ohio-Mississippi river basins [462].

Species

The genus Histoplasma contains one species, Histoplasma capsulatum. Histoplasma capsulatum has two varieties: Histoplasma capsulatum var. capsulatum and Histoplasma capsulatum var. duboisii. It has a teleomorph referred to as Ajellomyces capsulatus [1295, 2144, 2202].

Synonyms

See the summary of synonyms and teleomorph-anamorph relations for the Histoplasma sp.

Pathogenicity and Clinical Significance

Histoplasma capsulatum is the causative agent of a true systemic (endemic) mycosis called histoplasmosis. The spectrum of the disease is wide, varying from an acute benign pulmonary infection to a chronic pulmonary or fatal disseminated disease. Following acquisition of the conidia by inhalation, lungs are primarily involved. In cases of dissemination of Histoplasma capsulatum var. capsulatum infection, reticuloendothelial system (RES) is most frequently involved. The fungus resides intracellularly in RES cells [2067]. Histoplasma capsulatum may also rarely involve the thyroid glands and may be isolated in fungemia [201, 512, 716, 858]. Unlike var. capsulatum, var. duboisii rarely involves the lungs but commonly involves the bones and skin. Var. duboisii is the causative agent of African histoplasmosis [930].

Given the true systemic nature of histoplasmosis, otherwise healthy individuals are affected. However, dissemination and fatal course are more common in the immunocompromised and elderly. Chronic cavitary histoplasmosis is most commonly observed in individuals with underlying pulmonary disease [462, 2202].

Macroscopic Features

Being a thermally dimorphic fungus, Histoplasma capsulatum grows in mould form at 25°C, and in yeast form at 37°C. Below are the macroscopic characteristics at varying temperatures and for both varieties [1295, 2144].

At 25°C
Colonies are slow growing and granular to cottony in appearance. The color is white initially and usually becomes buff brown with age. The colonies are not sensitive to cycloheximide in the culture media. From the reverse, a yellow or yellowish orange color may be observed. While these features are best observed on Sabouraud dextrose agar (SDA), brain heart infusion agar (BHIA) enhances growth more efficiently.

At 37°C
Creamy, slowly growing, moist and yeast-like colonies are formed. This phase is observed in infected tissues and in vitro on enriched media, such as BHIA containing 5-10% blood.

For definitive identification of the fungus, yeast-to-mould conversion should be demonstrated.

Microscopic Features

At 25°C
Hyphae are septate and hyaline. Histoplasma capsulatum produces hyphae-like conidiophores which arise at right angles to the parent hyphae. It has both macro- and microconidia. Macroconidia are tuberculate, thick-walled, round, unicellular, hyaline, large and often have fingerlike projections on the surface. These macroconidia are also referred to as tuberculochlamydospores or macroaleurioconidia. Microconidia (microaleurioconidia) are unicellular, hyaline and round, with a smooth or rough wall.

At 37°C
Narrow-based, ovoid, budding yeast cells are formed. Yeasts of var. capsulatum are smaller than (2-4 µm) those of var. duboisii (12-15 µm) [1295, 2144].

Histopathologic Features

See our histopathology page.

Compare to

Chrysosporium, Sepedonium

Conversion to a yeast phase at 37°C, specific exoantigen testing, and nucleic acid hybridization methods differentiate Histoplasma capsulatum from both genera. Antigen detection in clinical samples offers a rapid way for diagnosis of histoplasmosis [2416] [749]. Also, Chrysosporium does not produce tuberculate macroconidia and Sepedonium does not produce microaleuriconidia [2144].

Laboratory Precautions

Isolates of Histoplasma must be handled with caution in a biological safety cabinet.

Susceptibility

Data on in vitro activity of Histoplasma capsulatum are yet limited. The NCCLS antifungal susceptibility testing methods have not been standardized for testing the activity of this fungus. Amphotericin B, voriconazole, itraconazole, and posaconazole in general yield relatively low MICs for Histoplasma capsulatum [683, 1152, 1338]. Fluconazole generally appears active, but resistance may develop [2413]. The echinocandins, caspofungin and anidulafungin have relatively higher MICs [683], and one in vivo study found caspofungin to have little activity [1221].

Amphotericin B, itraconazole and fluconazole are currently used in treatment of histoplasmosis. Fluconazole is less active than itraconazole [1655, 2414] and is a second-line agent. Ketoconazole is also a second-line drug due to the availability of safer and more efficacious alternatives [36, 623, 858, 1371].

Search

PubMed

Nucleotides

GenBank

Useful Link

NIOSH page on protection of workers at risk for exposure to histoplasmosis



Histoplasma capsulatum macroconidia
At 25°C tuberculate macroconidia are formed on a hypha-like conidiophore
Histoplasma capsulatum culture
Culture of H. capsulatum growing on BHIA with 10% sheep blood
Histoplasma capsulatum yeast phase, intracellular budding yeast
At 35°C, as an intracellular budding yeast
histoplasma-capsulatum-culture
Culture of H. capsulatum



References

36. Akpuaka, F. C., H. C. Gugnani, and L. M. Iregbulam. 1998. African histoplasmosis: report of two patients treated with amphotericin B and ketoconazole. Mycoses. 41:363-364.

201. Bauder, B., A. Kubber-Heiss, T. Steineck, E. S. Kuttin, and L. Kaufman. 2000. Granulomatous skin lesions due to histoplasmosis in a badger (Meles meles) in Austria. Med Mycol. 38:249-253.

462. Collier, L., A. Balows, and M. Sussman. 1998. Topley & Wilson's Microbiology and Microbial Infections, 9th ed, vol. 4. Arnold, London, Sydney, Auckland, New York.

512. Darling, S. T. 1909. The morphology of the parasite (Histoplasma capsulatum) and the lesions of histoplasmosis, a fatal disease of tropical America. J. Exp. Med. 11:515-530.

623. Drouhet, E., and B. Dupont. 1983. Laboratory and clinical assessment of ketoconazole in deep-seated mycoses. Am. J. Med. 74 (Suppl. 1b):30-47.

683. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 36:2950-2956.

716. Farina, C., F. Vailati, A. Manisco, and A. Goglio. 1999. Fungaemia survey: a 10-year experience in Bergamo, Italy. Mycoses. 42:543-548.

749. Fojtasek, M. F., M. B. Kleiman, P. Connolly-Stringfield, R. Blair, and L. J. Wheat. 1994. The Histoplasma capsulatum antigen assay in disseminated histoplasmosis in children. Pediatric Infectious Disease Journal. 13:801-805.

858. Goldani, L. Z., C. Klock, A. Diehl, A. C. Monteiro, and A. L. Maia. 2000. Histoplasmosis of the thyroid. J Clin Microbiol. 38:3890-3891.

930. Gugnani, H. C., and F. Muotoe-Okafor. 1998. African histoplasmosis: a review. Rev. Iberoam. Micol. 14:155-159.

1152. Kappe, R. 1999. Antifungal activity of the new azole UK-109, 496 (voriconazole). Mycoses. 42:83-86.

1221. Kohler, S., L. J. Wheat, P. Connolly, C. Schnizlein-Bick, M. Durkin, M. Smedema, J. Goldberg, and E. Brizendine. 2000. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. 44:1850-1854.

1295. Larone, D. H. 1995. Medically Important Fungi - A Guide to Identification, 3rd ed. ASM Press, Washington, D.C.

1338. Li, R. K., M. A. Ciblak, N. Nordoff, L. Pasarell, D. W. Warnock, and M. R. McGinnis. 2000. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis and Histoplasma capsulatum. Antimicrob. Agents Chemother. 44:1734-1736.

1371. Lortholary, O., D. W. Denning, and B. Dupont. 1999. Endemic mycoses: a treatment update. J Antimicrob Chemother. 43:321-331.

1655. Norris, S., J. Wheat, D. McKinsey, D. Lancaster, B. Katz, J. Black, M. Driks, R. Baker, K. Israel, D. Traeger, S. Moriarity, J. Fraiz, D. Webb, and T. Slama. 1994. Prevention of relapse of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am. J. Med. 96:504-508.

2067. Sebghati, T. S., J. T. Engle, and W. E. Goldman. 2000. Intracellular parasitism by Histoplasma capsulatum: Fungal virulence and calcium dependence. Science. 290:1368-1372.

2144. St-Germain, G., and R. Summerbell. 1996. Identifying Filamentous Fungi - A Clinical Laboratory Handbook, 1st ed. Star Publishing Company, Belmont, California.

2202. Sutton, D. A., A. W. Fothergill, and M. G. Rinaldi (ed.). 1998. Guide to Clinically Significant Fungi, 1st ed. Williams & Wilkins, Baltimore.

2413. Wheat, J., P. Marichal, H. Vanden Bossche, A. L. Monte, and P. Connolly. 1997. Hypothesis on the mechanisms of resistance to fluconazole in Histoplasma capsulatum. Antimicrob. Agents Chemother. 41:410-414.

2414. Wheat, J., S. MaWhinney, R. Hafner, D. McKinsey, D. Chen, A. Korzun, K. J. Shakan, P. Johnson, R. Hamill, D. Bamberger, P. Pappas, J. Stansell, S. Koletar, K. Squires, R. A. Larsen, T. Cheung, N. Hyslop, K. K. Lai, D. Schneider, C. Kauffman, M. Saag, W. Dismukes, W. Powderly, and National Institute of allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Myocses Study Group. 1997. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am. J. Med. 103:223-232.

2416. Wheat, L. J., P. Connolly-Stringfield, R. B. Kohler, P. T. Frame, and M. R. Gupta. 1989. Histoplasma capsulatum polysaccharide antigen detection in diagnosis and management of disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am. J. Med. 87:396-400.



  Home | Image Bank | Lecture Bank | Knowledgebase | Site Map | Contact Us |
The Fungi | Mycoses | Drugs |
Laboratory | Education & Tools | About Us

  bttm_banner_indv2_02[1].gif